title: [Interferon therapy for chronic myelogenous leukemia].
abstract: Interferon alpha (IFN alpha) has been used in the treatment of chronic myelogenous leukemia (CML). The initial trial was made in 1983 by Talpaz et al. Their first report suggested that IFN alpha treatment could achieve high hematological remission. The cause of the effect was unclear, but may be mediated through interaction cell surface membrane and inhibitory protein production. IFN alpha was related to some T cell immunity, and could be taken to be Ph1 positive cell inhibition by normal T cell. Although IFN alpha therapy has limited use with get Ph1 negative hematopoiesis, intensive treatment of this kind is needed to minimize Ph1 clone, using various therapy combination with IFN alpha.
authors.affiliation: First Dept. of Internal Medicine, Niigata University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Shibata
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007111:Immunity, Cellular; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016898:Interferon-alpha; D003561:Cytarabine; D014750:Vincristine; D007371:Interferon-gamma; D006918:Hydroxyurea; D003630:Daunorubicin